Pepsinogen I (PGI) is mainly used to evaluate the function of gastric secretory gland cells, and Pepsinogen II (PGII) is mainly used to evaluate gastric fundic mucous gland lesions.
Applicable to various sample types of serum, plasma and whole blood
Rapid detection of single reagent (10 minutes)
Convenient storage and transportation at room temperature
Successfully obtained in the EU CE access certification.
Clinical significance:
PGII is mainly a marker of gastric body atrophic gastritis, which is elevated in inflammation and decreases significantly in atrophic gastritis, precancerous lesions or gastric cancer, and is negatively correlated with gastric body atrophic gastritis.
PGII is mainly a marker of gastric inflammation, including gastric ulcer, duodenal ulcer, Helicobacter pylori (Hp) infection, PGII is significantly elevated in inflammation, positively correlates with gastric inflammation, and has a characteristic: it maintains a high level after elevation, and does not decrease significantly in atrophic gastritis, precancerous lesions or gastric cancer.
Main clinical applications:
1.For primary screening of gastric cancer and gastric diseases;
2.Evaluation of Hp and Eradication Treatment Effectiveness;
3.Screening for peptic ulcers.
Applicable departments:
Endoscopy Center, Gastroenterology, Physical Examination Center, etc.
Sample type:serum, plasma and whole blood
Report time:10min
Reference range:PGI >70ng/mL; PGII <15ng/mL
Storage:4-30℃,sealed and kept away from light and dry
Validity period:18months
Specifications:25 tests/box,50 tests/box